Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

In the Media

  • August 16, 2021

What impacts the cost of manufacturing synthesized cannabinoids?

What affects the cost of cannabinoid manufacturing?

To make rare cannabinoids commercially viable products, a high yielding and cost-effective method is required. What impacts the cost and yield of synthesized cannabinoids? A number of components can impact the cost of cannabinoid manufacturing. View this infographic for details.

  • Cost of starting materials – What are the building blocks needed to run the manufacturing process? Selecting the most cost-efficient substrates, or starting materials, and optimizing the use of these sophisticated starting materials can greatly reduce the overall manufacturing cost.
  • Efficiency of materials used – How effective are the enzymes at combining the starting substrates to produce the desired cannabinoid? To generate a higher yield level, it’s important to produce a high efficiency enzyme to be used in the bulk cannabinoid manufacturing downstream process.
  • Number of manufacturing steps – How many manufacturing steps are required? As expected, additional steps in the manufacturing process likely result in longer processing time and more materials used.
  • Nature of manufacturing process – How complicated are the process steps? The complexity of the process also results in a longer manufacturing time and additional GMP requirements. Finding efficiencies in the manufacturing steps is key to reducing the manufacturing costs.
  • Length of manufacturing process – How long does the process take? Minimizing the length of the the manufacturing cycle allows for greater volume of product in any given time period and optimizes the use of equipment.
  • Required standard of finished product – Is this a wellness, functional food or pharmaceutical product? What is the cost differential to manufacture to each of those different standards? The level of quality and purity needed will depend on the use of the product. There are different GMP standards for different product types. Pharmaceutical standard, for therapeutic use, is the most stringent and the standards required are the most costly to achieve.
  • Yield level – How much product is made from the process? How much product is lost during purification? The yield is dependant on the conversion of the starting substrates to the final product and varies from cannabinoid to cannabinoid. If there is double the yield level using the same materials and length of time, there is 200% more product at the same cost of manufacturing
Full Article

Share this post

Latest Articles

Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk

Article featured in Fierce Biotech October 16, 2025 Excerpt:  New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated

Read More
October 27, 2025

InMed Presents at the 2025 Life Sciences Investor Forum

Video Replay Now Available: InMed’s CEO, Eric A. Adams, presents at the 2025 Life Sciences Investor Forum. In the presentation, which was originally published on

Read More
October 14, 2025

InMed presents INM-901 data at 2025 Alzheimer’s Association International Conference

InMed presented data from its INM-901 Alzheimer’s disease program at the 2025 Alzheimer’s Association International Conference held in Toronto, Canada. The latest study presented in

Read More
August 18, 2025
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*